The present invention relates to a pharmaceutical composition comprising a tyrosine kinase inhibitor and one or more pharmaceutically acceptable excipients, a process for preparing such pharmaceutical composition and its use in the treatment of renal cell carcinoma and soft tissue sarcoma.